Patients with non–[18F]fludeoxyglucose‐avid advanced hepatocellular carcinoma on clinical staging may achieve long‐term recurrence‐free survival after liver transplantation
Arno Kornberg, Bernadett Küpper, Andrea Tannapfel, Peter Büchler, Babette Krause, Ulrike Witt, Dietmar Gottschild, Helmut Friess – 17 August 2011 – There is increasing evidence that a relevant number of patients with hepatocellular carcinoma (HCC) exceeding the Milan criteria may benefit from liver transplantation (LT). We retrospectively analyzed the prognostic significance of [18F]fludeoxyglucose ([18F]FDG) positron emission tomography (PET) for identifying appropriate LT candidates with advanced HCC on clinical staging. Between 1995 and 2008, 111 patients with HCC were listed for LT.